Biopharmaceutical firm SAGE Therapeutics scored USD 20 million from ARCH Venture Partners and Third Rock Ventures in its Series B funding round.
SAGE Therapeutics
Breaking News
Subscribe to VCpost newsletter
Most Popular
- SSDI Payment April 2024: Who Will Receive Social Security Benefits Today?
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Indiana Children's Museum Reportedly Exposed Total Solar Eclipse Watchers to Measles
- How to Get IRS Unclaimed Tax Refunds: Here's What to Do If You Think You Have Pending Payments
- Kroger and Albertsons to Sell off 166 Stores in Effort to Gain Approval for Their $25 Billion Merger
- Philippines Wants US, Japan to Fund Freight Railway Project After It Drops Funding Talks With China
- Student Loan Forgiveness Processing for This Group of Borrowers Will Stop Next Week
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
